Literature DB >> 25116175

The coactivator PGC-1α regulates skeletal muscle oxidative metabolism independently of the nuclear receptor PPARβ/δ in sedentary mice fed a regular chow diet.

Joaquín Pérez-Schindler1, Kristoffer Svensson, Elyzabeth Vargas-Fernández, Gesa Santos, Walter Wahli, Christoph Handschin.   

Abstract

AIMS/HYPOTHESIS: Physical activity improves oxidative capacity and exerts therapeutic beneficial effects, particularly in the context of metabolic diseases. The peroxisome proliferator-activated receptor (PPAR) γ coactivator-1α (PGC-1α) and the nuclear receptor PPARβ/δ have both been independently discovered to play a pivotal role in the regulation of oxidative metabolism in skeletal muscle, though their interdependence remains unclear. Hence, our aim was to determine the functional interaction between these two factors in mouse skeletal muscle in vivo.
METHODS: Adult male control mice, PGC-1α muscle-specific transgenic (mTg) mice, PPARβ/δ muscle-specific knockout (mKO) mice and the combination PPARβ/δ mKO + PGC-1α mTg mice were studied under basal conditions and following PPARβ/δ agonist administration and acute exercise. Whole-body metabolism was assessed by indirect calorimetry and blood analysis, while magnetic resonance was used to measure body composition. Quantitative PCR and western blot were used to determine gene expression and intracellular signalling. The proportion of oxidative muscle fibre was determined by NADH staining.
RESULTS: Agonist-induced PPARβ/δ activation was only disrupted by PPARβ/δ knockout. We also found that the disruption of the PGC-1α-PPARβ/δ axis did not affect whole-body metabolism under basal conditions. As expected, PGC-1α mTg mice exhibited higher exercise performance, peak oxygen consumption and lower blood lactate levels following exercise, though PPARβ/δ mKO + PGC-1α mTg mice showed a similar phenotype. Similarly, we found that PPARβ/δ was dispensable for PGC-1α-mediated enhancement of an oxidative phenotype in skeletal muscle. CONCLUSIONS/
INTERPRETATION: Collectively, these results indicate that PPARβ/δ is not an essential partner of PGC-1α in the control of skeletal muscle energy metabolism.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25116175      PMCID: PMC4657154          DOI: 10.1007/s00125-014-3352-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  30 in total

1.  PPARdelta, but not PPARalpha, activates PGC-1alpha gene transcription in muscle.

Authors:  Elayne Hondares; Inés Pineda-Torra; Roser Iglesias; Bart Staels; Francesc Villarroya; Marta Giralt
Journal:  Biochem Biophys Res Commun       Date:  2007-01-25       Impact factor: 3.575

2.  Remodeling of calcium handling in skeletal muscle through PGC-1α: impact on force, fatigability, and fiber type.

Authors:  Serge Summermatter; Raphael Thurnheer; Gesa Santos; Barbara Mosca; Oliver Baum; Susan Treves; Hans Hoppeler; Francesco Zorzato; Christoph Handschin
Journal:  Am J Physiol Cell Physiol       Date:  2011-09-14       Impact factor: 4.249

3.  The nuclear receptor PPARβ/δ programs muscle glucose metabolism in cooperation with AMPK and MEF2.

Authors:  Zhenji Gan; Eileen M Burkart-Hartman; Dong-Ho Han; Brian Finck; Teresa C Leone; Emily Y Smith; Julio E Ayala; John Holloszy; Daniel P Kelly
Journal:  Genes Dev       Date:  2011-12-01       Impact factor: 11.361

4.  PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes.

Authors:  Michael Schuler; Faisal Ali; Céline Chambon; Delphine Duteil; Jean-Marc Bornert; Aubry Tardivel; Béatrice Desvergne; Walter Wahli; Pierre Chambon; Daniel Metzger
Journal:  Cell Metab       Date:  2006-11       Impact factor: 27.287

5.  Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta).

Authors:  J M Peters; S S Lee; W Li; J M Ward; O Gavrilova; C Everett; M L Reitman; L D Hudson; F J Gonzalez
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

6.  Peroxisome proliferator-activated receptor {gamma} coactivator 1{alpha} (PGC-1{alpha}) promotes skeletal muscle lipid refueling in vivo by activating de novo lipogenesis and the pentose phosphate pathway.

Authors:  Serge Summermatter; Oliver Baum; Gesa Santos; Hans Hoppeler; Christoph Handschin
Journal:  J Biol Chem       Date:  2010-08-17       Impact factor: 5.157

7.  Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet.

Authors:  Taro E Akiyama; Gilles Lambert; Christopher J Nicol; Kimihiko Matsusue; Jeffrey M Peters; H Bryan Brewer; Frank J Gonzalez
Journal:  J Biol Chem       Date:  2004-03-04       Impact factor: 5.157

8.  Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway.

Authors:  Xiaoli Feng; Zhidan Luo; Liqun Ma; Shuangtao Ma; Dachun Yang; Zhigang Zhao; Zhencheng Yan; Hongbo He; Tingbing Cao; Daoyan Liu; Zhiming Zhu
Journal:  J Cell Mol Med       Date:  2010-05-14       Impact factor: 5.310

9.  PPAR{delta} agonism activates fatty acid oxidation via PGC-1{alpha} but does not increase mitochondrial gene expression and function.

Authors:  Sandra Kleiner; Van Nguyen-Tran; Olivia Baré; Xueming Huang; Bruce Spiegelman; Zhidan Wu
Journal:  J Biol Chem       Date:  2009-05-12       Impact factor: 5.157

10.  Pharmacological activation of PPARbeta promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle.

Authors:  Céline Gaudel; Chantal Schwartz; Christian Giordano; Nada A Abumrad; Paul A Grimaldi
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-20       Impact factor: 5.900

View more
  11 in total

1.  Germline or inducible knockout of p300 or CBP in skeletal muscle does not alter insulin sensitivity.

Authors:  Vitor F Martins; Jessica R Dent; Kristoffer Svensson; Shahriar Tahvilian; Maedha Begur; Shivani Lakkaraju; Elisa H Buckner; Samuel A LaBarge; Byron Hetrick; Carrie E McCurdy; Simon Schenk
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-03-19       Impact factor: 4.310

2.  PGC-1α plays a pivotal role in simvastatin-induced exercise impairment in mice.

Authors:  Miljenko Valentin Panajatovic; François Singh; Noëmi Johanna Roos; Urs Duthaler; Christoph Handschin; Stephan Krähenbühl; Jamal Bouitbir
Journal:  Acta Physiol (Oxf)       Date:  2019-11-04       Impact factor: 6.311

Review 3.  Role of Nuclear Receptors in Exercise-Induced Muscle Adaptations.

Authors:  Barbara Kupr; Svenia Schnyder; Christoph Handschin
Journal:  Cold Spring Harb Perspect Med       Date:  2017-06-01       Impact factor: 6.915

Review 4.  Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis.

Authors:  Shreekrishna Lamichane; Babita Dahal Lamichane; Sang-Mo Kwon
Journal:  Int J Mol Sci       Date:  2018-03-22       Impact factor: 5.923

Review 5.  Endocrine Crosstalk Between Skeletal Muscle and the Brain.

Authors:  Julien Delezie; Christoph Handschin
Journal:  Front Neurol       Date:  2018-08-24       Impact factor: 4.003

6.  Analysis of the PPARD Gene Expression Level Changes in Football Players in Response to the Training Cycle.

Authors:  D Domańska-Senderowska; A Snochowska; P Szmigielska; Z Jastrzębski; A Jegier; J Kiszałkiewicz; K Dróbka; J Jastrzębska; D Pastuszak-Lewandoska; P Cięszczyk; A Maciejewska-Skrendo; P Zmijewski; E Brzeziańska-Lasota
Journal:  Balkan J Med Genet       Date:  2018-10-29       Impact factor: 0.519

Review 7.  Pharmacological targeting of exercise adaptations in skeletal muscle: Benefits and pitfalls.

Authors:  Martin Weihrauch; Christoph Handschin
Journal:  Biochem Pharmacol       Date:  2017-10-20       Impact factor: 5.858

Review 8.  Caloric restriction and exercise "mimetics'': Ready for prime time?

Authors:  Christoph Handschin
Journal:  Pharmacol Res       Date:  2015-12-02       Impact factor: 7.658

9.  MicroRNA-29a induces insulin resistance by targeting PPARδ in skeletal muscle cells.

Authors:  Yuehua Zhou; Pingqing Gu; Weijie Shi; Jingyun Li; Qun Hao; Xiaomei Cao; Qin Lu; Yu Zeng
Journal:  Int J Mol Med       Date:  2016-02-22       Impact factor: 4.101

10.  Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals.

Authors:  Ho-Shan Niu; Po-Ming Ku; Chiang-Shan Niu; Juei-Tang Cheng; Kung-Shing Lee
Journal:  Drug Des Devel Ther       Date:  2015-10-14       Impact factor: 4.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.